Skip to content
Biotechnology

Stem Cell Therapy Developed in Korea Begins Treatment for Parkinson’s Disease Patients Worldwide in Japan

Biostar Stem Cell Research Institute 2 mins read
  • Biostar Stem Cell Research Institute has received approval from Japan's Ministry of Health, Labor and Welfare to Treat Parkinson's Disease.
  • The combination of intravenous and spinal cord cavity administration is expected to increase the effectiveness of the treatment. This therapy may also be effective for other incurable neurological diseases.
  • The stem cells are cultured in special media produced by Nature Cell, an affiliate of Biostar Stem Cell Research Institute. This proprietary culture media contributes to the safety and effectiveness

SEOUL, SOUTH KOREA / ACCESSWIRE / November 20, 2023 / Korea's leading adult stem cell research institute, Biostar Stem Cell Research Institute (Director: Dr. Jeongchan Ra), announced on the 20th that a regenerative medicine technology that treats Parkinson's disease by administering autologous fat-derived stem cells cultured using patented technology into the intravenous and spinal cord cavity has been approved by the Japanese Ministry of Health and Welfare and will begin treatment at the Shinjuku Clinic in Tokyo in December.

The approved stem cell treatment protocol involves administering 150 to 250 million fat-derived stem cells intravenously and 50 million cells into the spinal cord cavity five times at intervals of two to four weeks. The stem cells are either obtained from the Biostar Stem Cell Research Institute in Korea or from JASC, a Japanese affiliate.

The approval of stem cell treatment for Parkinson's disease marks a significant milestone in the clinical application of stem cells by the Biostar Stem Cell Research Institute, which began its research in 2008. The institute has previously received stem cell therapies for degenerative arthritis, severe lower extremity ischemia, and autoimmune diseases, administrated through intraarticular, intramuscular, and intravenous routes, respectively. The intravenous and spinal cord cavity administration of stem cells for Parkinson's disease further demonstrates the versatility and safety of Biostar's stem cell culture technology.

Stem cells vary greatly in safety and effectiveness depending on the culture method, highlighting the importance of rigorous quality management. The Biostar Stem Cell Research Institute's two-decade-long research on stem cell culture and treatment technologies, including the recently approved Parkinson's disease therapy, holds promise for developing new avenues for treating neurological disorders. The specialized culture media developed by the Biostar Stem Cell Research Institute, exclusively manufactured and supplied by its affiliate Nature Cell, plays a crucial role in enhancing the effectiveness and safety of these therapies.

The Biostar Stem Cell Research Institute is committed to expanding treatment-approved hospitals across Japan and intensifying global outreach, aiming to make Japan a destination for Parkinson's disease patients worldwide to regain their health.

Parkinson's disease affects an estimated 10 million people worldwide, with a rapidly growing prevalence, and remains an incurable condition without a definitive treatment.

Contact Information

Herim Park
Marketing Manager
herim16@stemcellbio.com
+81-75-662-7171

Anna Woo
Marketing Manager
anna@jasc-inc.jp
+81-75-662-7171

SOURCE: Biostar Stem Cell Research Institute

.


View source version on accesswire.com:
https://www.accesswire.com/806959/stem-cell-therapy-developed-in-korea-begins-treatment-for-parkinsons-disease-patients-worldwide-in-japan

More from this category

  • Biotechnology, Environment
  • 18/04/2024
  • 11:03
Wilderlands

Wilderlands protects 100,000 square metres of vulnerable Australian habitat through biodiversity credits.

Wilderlands have reached a major milestone becoming the world’s fastest voluntary biodiversity credit developer to retire over 100,000 units which will protect over 10…

  • Contains:
  • Biotechnology
  • 18/04/2024
  • 00:22
Derm-Biome Pharmaceuticals, Inc

Derm-Biome Pharmaceuticals’ topical therapy shows positive results in preclinical skin cancer trial: drug prevents the development of precancerous skin conditions and treats existing skin cancers with no observable side effects.

VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditions and skin cancers are soaring in many parts of the world. Actinic keratosis (AK) is the most common form of precancer, with over 40 million Americans a year developing this condition. Treating AKs before the cells become cancerous and spread to other parts of the body is crucial. For those patients with multiple AKs, common treatment options are chemotherapy creams and photodynamic therapy. Although effective, these treatments come with significant side effects, such as redness, blistering, and peeling, with recovery times that can be lengthy and uncomfortable. The global actinic keratosis treatment market size is projected to reach as high as $10 billion USD by 2031, fuelled by increasing cases of AK and rising healthcare spending.Derm-Biome Pharmaceuticals is a Vancouver-based biopharmaceutical…

  • Biotechnology, Medical Health Aged Care
  • 16/04/2024
  • 11:26
Island Pharmaceuticals

Island reports highly positive new data from ISLA-101 Single Ascending Dose study

Island reports highly positive pharmacokinetic data and reconfirms strong safety / tolerability data for ISLA-101 from its 24-subject Single Ascending Dose clinical study Data analysis shows required levels of ISLA-101 concentration in the blood were observed after only a single dose, achieving the study's purpose This important new data is being used to prepare for Island's planned Phase 2a clinical trial in dengue fever MELBOURNE Australia, 16 April 2024: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; “Island”; “the Company”) is pleased to announce highly encouraging pharmacokinetics (PK) data from its ISLA-101 Single Ascending Dose study. ISLA-101 is…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.